UCSF Pediatric Focus

UCSF Tests Interatrial Shunt To Reduce Hospital Stay for Heart Failure Patients

Less risk, less blood loss and shorter hospital stays are some of the potential advantages of a new interatrial shunt, according to interventional cardiologists at UCSF. The transcatheter implant in the atrial septum relieves pressure on the left side of the heart and redistributes it to the right side. On Dec. 14, 2018, UCSF became the second center in the country to implant the shunt in a clinical trial.

Vaikom Mahadevan, MD Cardiologist, UCSFInpatient transcatheter procedures, such as the interatrial shunt, can often be game changers – not just for patients with heart failure, but for those with any type of valvular disease, says Vaikom Mahadevan, MD, (left) director of Structural and Adult Congenital Cardiac Interventions at UCSF. “In some cases, patients can go home the same day, and many go home within 24 hours.”

In addition, transcatheter innovations are dramatically expanding therapeutic options for patients with heart disease. UCSF teams have been at the forefront of this therapy including:

  • percutaneous mitral valve replacement,
  • transcatheter valve therapy for severe tricuspid regurgitation,
  • use of a transcatheter valve for pulmonary valve dysfunction
  • and placement of a TAVR valve in the pulmonic position to address symptoms of carcinoid heart disease.

The division now has a number of new studies in the pipeline for patients with valvular disease who are not surgical candidates or who prefer a less invasive approach.